<DOC>
	<DOCNO>NCT00949351</DOCNO>
	<brief_summary>Activation renin-angiotensin play crucial role diabetic nephropathy . Angiotensin convert enzyme inhibitor ( ACEI ) Angiotensin I receptor blocker ( ARB ) show renoprotection whether use alone combination . Aliskiren direct renin inhibitor ( DRI ) show renal benefit safety combine ARB . However , date , safety add aliskiren combination treatment ACEI ARB diabetic nephropathy patient remain elucidate .</brief_summary>
	<brief_title>Safety Add Aliskiren Angiotensin Converting Enzyme Inhibitor ( ACEI ) Angiotensin I Receptor Blocker ( ARB ) Treatment Type 2 Diabetes With Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<criteria>Type2 diabetes patient Age &lt; 30yrs70yrs &gt; Overt proteinuria ( Urinary protein creatinine ratio &gt; 200mg/g 2 time past 6 Mo ) Scr &lt; 2.5 mg/dL HbA1C &lt; 7.5 Systolic blood pressure &gt; 160 mmHg without antihypertensive drug &gt; 140 antihypertensive drug No history previous cardiovascular event ( Stroke , Myocardial infarction , unstable angina , hospitalization , surgical correction PVD PVD claudication ) No hospitalization within 1 yr except elective surgery Physical examination find suspect serious comorbid ( AF , carotid bruit , structural heart disease , cirrhosis decompensate liver disease ) Non adherence protocol Intolerable ACEI ARB runin Abnormal liver function test runin period Rapid decline renal function ( SCr increase &gt; 40 % ) runin Hyperkalemia ( serum K &gt; 5.5 mEq/L randomization ) Malignancy detect SBP low 110 mmHg ( randomization )</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>ACEI , ARB , DN , aliskiren , proteinuria</keyword>
</DOC>